Arlington Medical Resources (AMR), a provider of premier market intelligence for the pharmaceutical and diagnostic imaging industries, finds that the total number of patients undergoing CT angiography (CTA) of the chest in the second quarter of 2008 has increased by 56 percent when compared to the second quarter of 2007. CTA is a non-invasive medical test that takes pictures of the blood vessels to help diagnose conditions in the neurovascular, chest and pulmonary, peripheral vasculature, abdomen and pelvis and coronary arteries.
The newly released edition of the Angiography Market Guide also finds that Italy performed the most non-cardiac CTA procedures of the chest in the second quarter of 2008 when compared to Germany, France, Italy, UK and Spain.
"Non-cardiac CTAs of the chest continue to show strong growth in the European markets," stated Anna Fisher, analyst at AMR. "A CTA is usually ordered in emergency rooms to check for life threatening conditions such as pulmonary embolism or aortic dissections."
Why Pharmaceutical and Medical Device Companies Need this Information
The Angiography Market Guide enables pharmaceutical and medical device companies to examine the rates of angiography procedures and to monitor the transition from traditional angiography to CTA and MR angiography (MRA) in Germany, France, Italy, UK and Spain. It is the industry's most comprehensive data available to capture the angiography market's procedure volumes for the various anatomical categories as well as patient demographics, clinical reason for performing the procedure, referring physician specialty, site delineation, enhancement agent name and dosing, pressure injector use and magnet strength.
About the Angiography Market Guide
The Angiography Market Guide is a supplement to the Imaging Market Guide designed to capture the nuances of the angiography market, including CT angiography, MR angiography (MRA) and XR angiography. The audit is conducted twice a year.
AMR (www.AMR-data.com) serves the market intelligence needs of the pharmaceutical and diagnostic imaging industries. Research includes clinical inpatient databases that directly link anti-infective drug with indication/procedure, formulary and stocking status tracking studies, drug purchasing audits and diagnostic imaging procedure volume/contrast media usage audits.
About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.
All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact: Natalia Morales Elizabeth Marshall Decision Resources Decision Resources, Inc. 781-296-2691 781-296-2563 email@example.com firstname.lastname@example.org
First Call Analyst:
SOURCE: Arlington Medical Resources
CONTACT: Natalia Morales, Decision Resources, +1-781-296-2691,
email@example.com; or Elizabeth Marshall, Decision Resources, Inc.,